The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The challenges of oral drug delivery via nanocarriers
Open accessAbstract
The oral application of pharmaceuticals is unarguably the most convenient method of application. Especially for protein- or peptide-based drugs, however, the effectiveness is significantly reduced due to enzymatic digestion in the stomach as well as a poor bioavailability in the small intestine. For these difficult formulations, the encapsulation into nanocarriers would protect the sensitive drug and thus could considerably improve the efficiency of oral drug delivery. In the last years, many candidate biodegradable nanomaterials for such carrier systems have been published. However, before the cargo can be released, the nanocarrier needs to cross multiple barriers of the human body, including a layer of intestinal mucus and epithelial as well as endothelial cells. For overcoming these cellular barriers, transcytosis is favored over a paracellular transport for most nanomaterials as paracellular transport routes lack selectivity of transported molecules once opened up. The exact mechanisms behind the transcellular translocations are up to now still not completely understood. For the vast majority of nanocarriers, the rate of transcellular transport is not sufficient to realize their application in oral drug delivery. Especially trafficking into the endolysosomal pathway often marks a key problem. In this review, we focus on the molecular mechanisms of overcoming cellular barriers, especially transcytosis, and highlight difficulties of oral drug delivery via nanocarriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Lysosomal acidification mechanisms
Mindell, J. A. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142317 · Cited by 1,258
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
Lai, S. K., O'Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608611104 · Cited by 1,050
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R., & Mahajan, A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.30 · Cited by 721 · cited 1×
“Their natural function is the transcytosis of antigens across the gut epithelium (Mabbott et al., 2013).”
BackgroundHarush-Frenkel, O., Rozentur, E., Benita, S., & Altschuler, Y. (2008) · Biomacromolecules · doi:10.1021/bm700535p · Cited by 405
Frey, A., Giannasca, K. T., Weltzin, R., Giannasca, P. J., Reggio, H., Lencer, W. I., & Neutra, M. R. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1045 · Cited by 401
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination
Garinot, M., Fiévez, V., Pourcelle, V., Stoffelbach, F., des Rieux, A., Plapied, L., Theate, I., Freichels, H., Jérôme, C., Marchand-Brynaert, J., et al. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.021 · Cited by 331
Lectin-mediated mucosal delivery of drugs and microparticles
Clark, M. A., Hirst, B. H., & Jepson, M. A. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00070-3 · Cited by 236
Ho, Y. T., Kamm, R. D., & Kah, J. C. Y. (2018) · Nanoscale · doi:10.1039/c8nr02393j · Cited by 102 · cited 1×
“To our knowledge, the only study so far that focused on the utilization of a protein corona for transcytosis reported differences in transcytosis efficiencies after the formation of a protein corona in HUVECs; however, these effects varied widely between different sized NPs (Ho et al., 2018).”
Background
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Hua, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00524 · Cited by 527
Advances in Oral Drug Delivery Systems: Challenges and Opportunities
Lou, J., Duan, H., Qin, Q., Teng, Z., Gan, F., Zhou, X., & Zhou, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020484 · Cited by 397
Khan, S., Sharma, A., & Jain, V. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.056 · Cited by 259
Plant-Derived Nanovesicles: Further Exploration of Biomedical Function and Application Potential
Li, A., Li, D., Gu, Y., Liu, R., Tang, X., Zhao, Y., Qi, F., Wei, J., & Liu, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.022 · Cited by 137
Metadata
- Authors
- Reinholz, J., Landfester, K., & Mailänder, V.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2018-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 1694-1705
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2899347457
- Cited by
- 233
- References
- 10
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The challenges of oral drug delivery via nanocarriers. https://app.cochat.ai/papers/10.1080/10717544.2018.1501119
- The paper
- Reinholz, J., Landfester, K., & Mailänder, V. (2018). The challenges of oral drug delivery via nanocarriers. Drug Delivery. https://doi.org/10.1080/10717544.2018.1501119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.